MedPath

Transcutaneous Electrical Nerve Stimulation (TENS) for Advanced Cancer Pain Patients

Not Applicable
Completed
Conditions
Advanced Cancer
Interventions
Device: Modulated TENS
Device: Placebo TENS
Registration Number
NCT02655289
Lead Sponsor
University Hospital Freiburg
Brief Summary

Pain is the most common symptom (ca. 80% of patients) on German Palliative Care units and thus, pain control plays a central role in palliative care.

Transcutaneous electrical nerve stimulation (TENS) is a complementary treatment option for patients who experience suboptimal pain control. However, the evidence for the efficacy of TENS in cancer patients is not unambiguous.

The present study is a double blind, placebo-controlled cross-over trial with a short-term follow-up.

The primary aim of this study is to evaluate the efficacy and safety of TENS for cancer pain reduction in advanced cancer patients.

The secondary aim is the explorative identification of subgroups that benefit or do not benefit from TENS.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
20
Inclusion Criteria
  • Patients with cancer pain (caused by tumor or therapy; or associated with tumor) ≥ 3 on an 11-point NRS the last 24 hours
  • Age: ≥ 18 years
  • Patients receive at least 24 hours palliative care: on palliative care ward, palliative care consultant service or acute pain consultant service
Exclusion Criteria
  • Verbal or cognitive inability to use TENS or to answer the questionnaire
  • High probability of dying within the next week
  • Pain that is not directly or indirectly related to tumor

Contraindications: Jones (2009) & Disselhoff (2012)

  • electronic implants like pacemakers
  • Metal implant on electrode site
  • Arrhythmia
  • Pregnancy
  • Epilepsy
  • Dermatological conditions or frail skin on electrode site
  • Anamnestically known distinct allergy regarding electrodes

Drop-out criteria after inclusion:

  • Patients that decide to stop TENS treatment (at any time or any reason).
  • Further treatment is not indicated due a rapid deterioration of the patients' clinical status according to the treating physician.

Study & Design

Study Type
INTERVENTIONAL
Study Design
CROSSOVER
Arm && Interventions
GroupInterventionDescription
Modulated TENSModulated TENS-
Placebo TENSPlacebo TENS-
Primary Outcome Measures
NameTimeMethod
Change of mean pain intensity last 24 hoursBefore and after the 24-hour-interventions and after the follow-up: at an average of one week

11-point Numerical Rating Scale (NRS): 0-10; 0=no pain; 10=pain as bad as you can imagine

Secondary Outcome Measures
NameTimeMethod
Change of worst pain intensity last 24 hoursBefore and after the 24-hour-interventions and after the follow-up: at an average of one week

11-point NRS

Change of least pain intensity last 24 hoursBefore and after the 24-hour-interventions and after the follow-up: at an average of one week

11-point NRS

Change of pain perception during TENS application on NRSAfter the 24-hour-interventions and after the follow-up: at an average of one week

11-point NRS 0-100%; 0% = no alleviation, 100% = complete alleviation

Change of pain perception during TENS application on VRSAfter the 24-hour-interventions and after the follow-up: at an average of one week

7-point verbal rating scale (VRS): 1= "very considerable deterioration", 2= "considerable deterioration", 3= "slight deterioration", 4= "unchanged", 5="slight improvement", 6= "considerable improvement", 7= "very considerable improvement"

Number and percent of respondersAfter the 24-hour-interventions and after the follow-up: at an average of one week

Responders: Patients with at least "slight improvement" on VRS (see outcome before) during TENS application

Quality of life last 24 hoursBefore and after the 24-hour-interventions and after the follow-up: at an average of one week

Question 30 from EORTC QLQ-C30

General ActivityBefore and after the 24-hour-interventions and after the follow-up: at an average of one week

11-point NRS

MoodBefore and after the 24-hour-interventions and after the follow-up: at an average of one week

11-point NRS

Walking abilityBefore and after the 24-hour-interventions and after the follow-up: at an average of one week

11-point NRS

Normal Work (includes both work outside the home and housework)Before and after the 24-hour-interventions and after the follow-up: at an average of one week

11-point NRS

Relations with other peopleBefore and after the 24-hour-interventions and after the follow-up: at an average of one week

11-point NRS

SleepBefore and after the 24-hour-interventions and after the follow-up: at an average of one week

11-point NRS

Enjoyment of lifeBefore and after the 24-hour-interventions and after the follow-up: at an average of one week

11-point NRS

Trial Locations

Locations (1)

Clinic for Palliative Care, Medical Center, University of Freiburg

🇩🇪

Freiburg, Germany

© Copyright 2025. All Rights Reserved by MedPath